Lifecare ASA

Share Issue/Capital Change • Apr 25, 2024

LIFECARE AS: KEY INFORMATION RELATING TO THE PREFERENTIAL RIGHTS ISSUE

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Reference is made to the stock exchange announcement published by Lifecare AS ("Lifecare" or the "Company") on 25 April 2024, regarding the proposal by the board of directors to increase the share capital of the Company through issuance of new shares in the Company (the "New Shares") through a partially underwritten rights issue with preferential subscription rights for existing shareholders (the "Subscription Rights"), raising gross proceeds of minimum NOK 75 million and up to NOK 90 million (the "Rights Issue"). Please see the following preliminary key information relating to the Rights Issue included below.

Date on which the terms and conditions of the Rights Issue were announced: 25 April 2024

Last day including right: 16 May 2024

Ex-date: 21 May 2024

Record Date: 22 May 2024

Date of approval: 16 May 2024

Maximum number of New Shares: To be announced when clarified

Subscription price: To be announced when clarified

Ratio preferential rights: To be announced when clarified

Subscription ratio: To be announced when the final number of New Shares is determined

Manager: Carnegie AS

Will the rights be listed: The Company will apply for trading of the Subscription Rights on Euronext Growth Oslo

ISIN for the preferential rights: To be announced when clarified

Other information: The subscription price for the New Shares to be issued in the Rights Issue, and thus the final number of New Shares and the exact amount of the share capital increase will be proposed by the board of directors, based on a recommendation from the manager, the day prior to the extraordinary general meeting to be held on or about 16 May 2024 (the "EGM"). Pursuant to the underwriting agreements for the Rights issue, the subscription price in the Rights Issue shall be the theoretical ex rights price (TERP) based on the volume-weighted average price (VWAP) of the Company's shares on Euronext Growth Oslo the three trading days prior to the EGM, less a discount of at least 35%. However, the maximum subscription price for the New Shares shall not exceed a 15% premium to the TERP calculated based on the last closing price of the Company's shares on Euronext Growth Oslo prior to the Company's announcement of the partially underwritten Rights Issue less a discount of at least 35%. The board of directors' resolution in this respect will be announced through a stock exchange announcement on the day prior to the EGM and be reflected in the final proposed resolution to the EGM. See the stock exchange announcement published on 25 April 2024 for further information regarding the Rights Issue. The Rights Issue is subject to approval by the EGM. The notice of the EGM is expected to be sent on or about 2 May 2024.

Disclosure regulation

This information is published in accordance with the requirements of the Continuing Obligations for issuers listed on Euronext Growth Oslo.

About us

Lifecare AS is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's main focus is to bring the next generation of Continuous Glucose Monitoring ("CGM") systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors ("NTR") on the sensor body for read-out of pressure variations. Lifecare's sensor technology is referred to as "Sencell" and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40

Asle Wingsternes, Head of Communications & Public Affairs, asle.wingsternes@lifecare.no, +47 41 61 42 52

This information has been submitted pursuant to the Securities Trading Act § 5-12 and MAR Article 19 no. 3. The information was submitted for publication at 2024-04-25 20:01 CEST.